NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free SGMO Stock Alerts $0.52 +0.01 (+1.97%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.50▼$0.5350-Day Range$0.49▼$1.3852-Week Range$0.29▼$1.78Volume662,849 shsAverage Volume1.52 million shsMarket Capitalization$107.44 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sangamo Therapeutics alerts: Email Address Sangamo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside994.4% Upside$5.67 Price TargetShort InterestBearish6.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.54) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector783rd out of 916 stocksBiotechnology Industry15th out of 24 stocks 3.3 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.39% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Sangamo Therapeutics has recently increased by 16.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 1.9 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.54) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Sangamo Therapeutics Stock (NASDAQ:SGMO)Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.Read More SGMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMO Stock News HeadlinesApril 27, 2024 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Research Coverage Started at StockNews.comApril 23, 2024 | americanbankingnews.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Hold" from BrokeragesApril 28, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 23, 2024 | americanbankingnews.comSangamo Therapeutics Sees Unusually Large Options Volume (NASDAQ:SGMO)April 22, 2024 | businesswire.comSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 2, 2024 | msn.comBiotech Roundtable: Who will bring the next CRISPR drug to market?March 25, 2024 | finance.yahoo.comWhat You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade TodayMarch 19, 2024 | money.usnews.comSangamo Therapeutics IncApril 28, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 16, 2024 | ca.finance.yahoo.comSGMO Apr 2024 1.500 putMarch 16, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)March 16, 2024 | finance.yahoo.comSGMO Apr 2024 1.500 callMarch 15, 2024 | finance.yahoo.comSGMO Apr 2024 3.000 callMarch 14, 2024 | finance.yahoo.comSangamo Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | markets.businessinsider.comSangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy RatingMarch 13, 2024 | markets.businessinsider.com4 Analysts Assess Sangamo Therapeutics: What You Need To KnowMarch 13, 2024 | businesswire.comSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | businesswire.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastMarch 1, 2024 | finance.yahoo.comSangamo Therapeutics, Inc. (SGMO)February 23, 2024 | investing.comSangamo Therapeutics (SGMO) Earnings Dates & ReportsFebruary 13, 2024 | markets.businessinsider.comSangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial UncertaintiesFebruary 12, 2024 | markets.businessinsider.comSangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920February 12, 2024 | finance.yahoo.comWith 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional ownersFebruary 12, 2024 | finance.yahoo.comSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseFebruary 7, 2024 | msn.comSangamo’s STAAR Study Shows Promise in Fabry Disease TreatmentFebruary 5, 2024 | finance.yahoo.comSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileJanuary 19, 2024 | markets.businessinsider.comDeep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)See More Headlines Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees405Year Founded1995Price Target and Rating Average Stock Price Target$5.67 High Stock Price Target$10.00 Low Stock Price Target$1.00 Potential Upside/Downside+994.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-257,830,000.00 Net Margins-146.30% Pretax Margin-149.18% Return on Equity-82.17% Return on Assets-56.21% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual Sales$176.23 million Price / Sales0.61 Cash Flow$0.04 per share Price / Cash Flow14.06 Book Value$0.47 per share Price / Book1.10Miscellaneous Outstanding Shares207,500,000Free Float201,271,000Market Cap$107.44 million OptionableOptionable Beta1.39 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Alexander D. Macrae Ch.B (Age 61)M.B., MRCP, Ph.D., CEO, President & Director Comp: $722.67kDr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)Senior VP & Chief Development Officer Comp: $459.9kMs. Amy Pooler Ph.D.Head of ResearchMr. Gregory Davis Ph.D.Head of TechnologyMs. Aron FeingoldHead of Corporate Communications & Investor Relations OfficerMr. Scott B. Willoughby (Age 49)Senior VP, General Counsel & Corporate Secretary Phillip RamseyHead of Technical OperationsMs. Stephanie J. Seiler CLPHead of Business Development & Alliance ManagementMr. David OjalaScientist II - Discovery & Translational ResearchLouise WilkieVice President of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsCurisNASDAQ:CRISAgenusNASDAQ:AGENSAB BiotherapeuticsNASDAQ:SABSAlloVirNASDAQ:ALVRVigil NeuroscienceNASDAQ:VIGLView All CompetitorsInsiders & InstitutionsWasatch Advisors LPBought 7,734,400 shares on 4/18/2024Ownership: 11.253%Wasatch Advisors LPSold 5,588,857 shares on 2/14/2024Ownership: 6.991%Golden State Equity PartnersBought 34,960 shares on 2/2/2024Ownership: 0.113%Simplex Trading LLCBought 6,100 shares on 2/2/2024Ownership: 0.000%Federated Hermes Inc.Sold 103,255 shares on 1/31/2024Ownership: 0.192%View All Insider TransactionsView All Institutional Transactions SGMO Stock Analysis - Frequently Asked Questions Should I buy or sell Sangamo Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SGMO shares. View SGMO analyst ratings or view top-rated stocks. What is Sangamo Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued 12-month price objectives for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they anticipate the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 994.4% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts. How have SGMO shares performed in 2024? Sangamo Therapeutics' stock was trading at $0.5433 at the beginning of 2024. Since then, SGMO stock has decreased by 4.7% and is now trading at $0.5178. View the best growth stocks for 2024 here. When is Sangamo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SGMO earnings forecast. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.09. The biopharmaceutical company earned $2.04 million during the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative net margin of 146.30% and a negative trailing twelve-month return on equity of 82.17%. What ETFs hold Sangamo Therapeutics' stock? ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA).Morningstar US Small Growth (MSGR). What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC). Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (11.25%). Insiders that own company stock include Biogen Inc and John Markels. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SGMO) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
